30 Day Trial

Sanofi Reports 4Q18 Orthobiologic Revenue of €81MM, -5.8% vs. 4Q17


Sanofi reports 4Q18 Synvisc/Synvisc-One orthobiologics revenue of €81MM (USD $93.1MM), -5.8% vs. 4Q17, with 2018 full-year revenue of €313MM (USD $359.6MM), -19.1% vs. 2017.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.